trial

Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia

NCTId NCT02203838
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 500 (actual)
Sponsored by Indivior Inc.
Primary completion 2016-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
500 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2014-06
Primary completion
2016-09
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
RBP-7000

Sponsors

Indivior Inc.Lead Sponsor

Sites

48 total
Little Rock, United StatesSpringdale, United StatesCerritos, United StatesEscondido, United StatesGlendale, United StatesLong Beach, United StatesLong Beach, United StatesOakland, United StatesOceanside, United StatesPico Rivera, United StatesSan Diego, United StatesNorwalk, United States

Linked catalysts

1
Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia — primary completion2016-09

Facts & assertions

4 sourced
Enrollment
500
Phase
PHASE3
Primary Completion Date
2016-09
Status
COMPLETED
relationships
The graph out of here
drug
RBP-7000
drug
lead_sponsor
Indivior Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication